Respiratory Molecular Diagnostics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Technology (Polymer Chain Reaction And Next-Generation Sequencing), By Disease Indication (Viruses, Bacteria, And Others), By End-users (Hospital, Research Institution, Point Of Care Setting, And Diagnostic Laboratories) and Region

Respiratory Molecular Diagnostics Market is expected to grow at a compound annual growth rate (CAGR) of 7.1%. The rising prevalence of respiratory illnesses, particularly among the aging population, increased demand for advanced diagnostics with the integration of AI, data analysis, and technological advancements (imaging, molecular diagnostics, rapid tests) are fuelling the respiratory molecular diagnostics market. This growth is driven by the need for early detection, personalized treatment, and efficient response to outbreaks. Conversely, environmental pollution increases the patient pool, while the COVID-19 pandemic significantly boosted the market due to the need for accurate and rapid testing.

For instance, the World Health Organization reports that lower respiratory infections were among the top ten causes of death globally in 2019, highlighting the critical need for accurate and timely diagnostics. Additionally, the emergence of antimicrobial resistance has further emphasized the importance of precise pathogen identification for targeted therapy. However, challenges such as high initial costs of molecular diagnostic systems, the need for skilled personnel, and issues related to test standardization and quality control may hinder market growth to some extent. Hospitals adopted stricter protocols to prevent cross-infection during the pandemic, leading to increased focus on respiratory diagnostics. However, the high cost of advanced technologies for diagnostics and the limited resources and awareness remain challenges and hurdles.

Respiratory Molecular Diagnostics Market Key Developments:

• In 2023, The Alinity m Resp-4-Plex assay, a one-step test approved by the FDA, detects and differentiates between SARS-CoV-2, influenza A/B, and respiratory syncytial virus.
• August 2, 2023, Becton, Dickinson and Company (BD) has received 510(k) clearance from the US Food and Drug Administration (FDA) for its single molecular diagnostic combination test, BD Respiratory Viral Panel (RVP) for BD MAX System.
• In 2024, Roche launched its latest multiplex PCR assay, capable of simultaneously detecting and differentiating SARS-CoV-2, influenza A/B, and respiratory syncytial virus (RSV) from a single patient sample. This innovation aims to improve diagnostic efficiency and support rapid clinical decision-making during respiratory infection seasons.